Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC.
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and
safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after
resection in patients with biliary tract cancer.